Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 20/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 20/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 9/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 6/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469733 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2759466 | 0.95 | GABRG2 (0.90) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL248296 | 0.94 | GABRG2 (0.88) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL29528203 | 0.94 | GABRG2 (0.88) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL247567 | 0.94 | GABRG2 (0.88) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2759470 | 0.90 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL248220 | 0.90 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2654854 | 0.89 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL3410317 | 0.89 | GABRG2 (0.79) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL16625048 | 0.88 | GABRG2 (0.79) | GABRG2GABRB3GABRA3GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249483-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2022-08-11 | — | — | US | claimed |
| US-10588905-B2 | Compositions and methods for treatment of fragile X syndrome | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2020-03-17 | — | — | US | claimed |
| US-20190083493-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2019-03-21 | — | — | US | claimed |
| US-20160199373-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2016-07-14 | — | — | US | claimed |
| US-20150158870-A1 | POLYMORPHS OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE | CONCERT PHARMACEUTICALS INC. | 2015-06-11 | — | — | US | claimed |
| US-20150119398-A1 | FORM 2 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE | CONCERT PHARMACEUTICALS INC. | 2015-04-30 | — | — | US | claimed |
| US-20150099753-A1 | FORM 5 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE | CONCERT PHARMACEUTICALS INC. | 2015-04-09 | — | — | US | claimed |
| EP-1149102-B1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2004-12-08 | — | — | EP | claimed |
| US-20030158203-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | MERCK & CO., INC. | 2003-08-21 | — | — | US | claimed |
| EP-1149102-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-31 | — | — | EP | claimed |
| WO-2000044752-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-08-03 | — | — | WO | claimed |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12433898-B2 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2025-10-07 | — | — | US | disclosed |
| US-20250268912-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | UNIVERSITAT ZURICH (CH) | 2025-08-28 | — | — | US | disclosed |
| EP-1149102-B1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20030158203-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | MERCK & CO., INC. | 2003-08-21 | — | — | US | disclosed |
| US-6500828-B1 | TREATMENT OF ANXIETY AND CONVULSIONS | MERCK SHARP & DOHME LTD. (GB) | 2002-12-31 | — | — | US | disclosed |
| EP-1149102-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000044752-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199373-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | GABBR1, GABBR2, GABRE | GABRG2 12/4885GABRB3 4/4885GABRA3 5/4885 |
| US-20150158870-A1 | POLYMORPHS OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE | TAF9, TERT, TFDP2 | GABRG2 4439/4885GABRB3 4526/4885GABRA3 4468/4885 |
| US-10588905-B2 | Compositions and methods for treatment of fragile X syndrome | GABBR1, GABBR2, GABRE | GABRG2 12/4885GABRB3 4/4885GABRA3 5/4885 |
| US-20150119398-A1 | FORM 2 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE | TTI2, TTR, RIF1 | GABRG2 3433/4885GABRB3 3083/4885GABRA3 3122/4885 |
| US-20220249483-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | GABBR1, GABBR2, GABRE | GABRG2 12/4885GABRB3 4/4885GABRA3 5/4885 |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | HTR1D, HTR5A, PCNP | GABRG2 3641/4885GABRB3 1766/4885GABRA3 2464/4885 |
| US-20150099753-A1 | FORM 5 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE | RIF1, TTR, TERT | GABRG2 4165/4885GABRB3 4156/4885GABRA3 4200/4885 |
| US-20250268912-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | GABRB2, GABRB3, GABRB1 | GABRG2 8/4885GABRB3 2/4885GABRA3 9/4885 |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | FLNB, SETD1B, HTR5A | GABRG2 2547/4885GABRB3 701/4885GABRA3 1624/4885 |
| US-20190083493-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | GABBR1, GABBR2, GABRE | GABRG2 12/4885GABRB3 4/4885GABRA3 5/4885 |
| US-20030158203-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | GABBR1, GABRA3, GABRA5 | GABRG2 15/4885GABRB3 8/4885GABRA3 2/4885 |
| US-12433898-B2 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | GABRG2 8/4885GABRB3 2/4885GABRA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.